Long Term Outcome of Easophageal Atresia : Transmics Profiles in Adolescence

Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age13-14
SponsorUniversity Hospital, Lille

About this trial

Oesophageal atresia (OAEA), a malformation of the oesophagus present from birth, is characterized by the interruption of the continuity of the oesophagus, which then ends in a cul-de-sac. (Source: Fimatho) An operation is then required to restore continuity to the esophagus. Although this operation enables the vast majority of children to survive the neonatal period, health problems such as gastro-oesophageal reflux, eating difficulties, respiratory problems and growth problems persist throughout life.

The aim of the project is to create a prospective cohort of adolescents aged 13/14, nested in the national AO registry. of adolescents born with esophageal atresia, including a biobank of esophageal mucosa and plasma blood samples. Once the clinical and omic data have been collected, the data will be transferred to the France Cohortes information system for analysis, in order to assess the long-term outcome of this rare disease and establish multi-omic profiles. Once the clinical data have been collected and the omics data (derived from analysis of the biobank's biological samples) have been generated, they will be analyzed by the project partners to assess the long-term outcome of OA and establish multiomic profiles. The raw data will be available on the France Cohorte platform.

Eligibility criteria

Qualifiers

Born with oesophageal atresia (EA) in France or in French overseas departments and territories

Anastomosis performed

Included into the ReNaTo registry

Aged 13 or 14 during the recruitment period

Disqualifiers

Concurrent participation in an interventional trial and in the 3 months prior to inclusion

Parents refusing to participate in the study

Histologically non-normal esophageal biopsy

Parents refusing to participate in the study

Trial design

Treatments tested in this trial

  • Questionnaire

Treatment groups

300 Participants
are divided into 2 treatment groups

Sponsors and collaborators

University Hospital, Lille

Lead sponsor

Institut National de la Santé Et de la Recherche Médicale, France

Collaborator